Why sermorelin, ipamorelin and CJC 1295 dosage numbers don’t transfer
A number looks easy to carry from a paper into everyday life. The substance, route and purpose don’t travel so easily. I keep them together when reading dosage research.
The amount travels with the formulation
In Ionescu and Frohman’s CJC-1295 study, healthy men received a single dose of 60 or 90 micrograms per kilogram under the skin. Researchers measured hormone release using the DAC form. They weren’t testing an everyday routine or a blend with ipamorelin.
DAC is an attachment that helps CJC-1295 bind albumin, a blood protein, and stay around longer. The FDA’s review treats the version without DAC as a different active ingredient. It found no human study of that version.
In Gobburu’s human-volunteer study, ipamorelin was given into a vein. That route has its own evidence. The study doesn’t establish how another route behaves or what happens when ipamorelin is combined with a particular CJC form.
Sermorelin research cannot fill the gap. Wilton and colleagues studied GHRH(1–29) by intravenous and nasal routes in healthy men. Those results belong to that substance and those routes, rather than a CJC-1295 and ipamorelin schedule.
Neither ingredient has an FDA-approved drug label. The component studies don’t establish a regimen for the fixed pair. Even two accurately quoted amounts would leave the mixture, timing and intended use unresolved.
A prescription decision has a different job
A clinician has a different task from someone describing a paper: deciding whether care is appropriate for a person. Health history and the intended use matter. The safety review of hormone-releasing drugs raises questions about blood sugar and fluid build-up, without supplying personal instructions.
CJC-1295 Ipamorelin pairs growth hormone secretagogues, substances that encourage hormone release. Promise Peptides (mypromise.com) providers prescribe CJC-1295 blended with ipamorelin. Care is limited to the United States, where a licensed U.S. provider reviews your health history and decides whether to prescribe; some people may not qualify. The compounded medicine has no FDA approval.
An offering doesn’t settle the ingredient rules. CJC-1295 appears among the withdrawn nominations in FDA’s April 22, 2026 listing. Ipamorelin acetate is also withdrawn and remains in Category 2 under the 503B policy for outsourcing facilities. Withdrawal isn’t permission to compound; no withdrawal dates are given.
Useful questions for a care conversation include: which exact form is proposed? What evidence supports the intended use? How would the risks be considered? Whether an approved alternative addresses the medical problem is another question worth putting on the table.
The research page follows the studies. The test-report page explains what checking material can establish. Neither a study number nor a material report can decide whether a prescription is appropriate for you.
An experimental amount explains what researchers did. Choosing care for a person needs clinical judgement, and the pair’s missing trial remains missing.